Sri Kosaraju

Sri Kosaraju has served on our board of directors since April 2019. Since January 2026, Mr. Kosaraju has served as a global chair of investment banking for JPMorgan Chase & Co to support the firm's healthcare industry vertical. Sri previously served as President and Chief Executive Officer of Inscripta from October 2020 to April 2025 when that company was merged with Manus Bio. He has served on the board of Manus Bio since April 2025 and on the board of Nevro Corp., a publicly traded medical device company, from August 2021 to April 2025. He has been a member of the board of directors for Hertz Foundation since October 2025. Previously, Mr. Kosaraju served as President of Penumbra, a publicly traded medical device company, from August 2019 to May 2020, Chief Financial Officer from May 2015 to November 2019 and as Head of Strategy from May 2015 to August 2019. Prior to joining Penumbra, he worked in investment banking for J.P. Morgan Securities LLC from 1999 to May 2015, where he held a variety of positions with successively greater responsibility including Managing Director of Equity Capital Markets, Head of Healthcare Equity Capital Markets and co-Head of Technology, Media, Telecom Equity Capital Markets. Prior to entering J.P. Morgan’s equity capital markets group in 2006, Mr. Kosaraju served in various practice groups at J.P. Morgan, including Equity Derivatives from 2003 to 2006 and Technology, Media, Telecom Investment Banking Coverage from 1999 to 2003. He received a B.S. from Massachusetts Institute of Technology in 1999.